STAAR Surgical Company: financial statements

STAANASDAQHealthcare · Ophthalmic Goods

Price

$26.01

November 16, 2026Market cap $1.3B

What Ploutos Investor adds for STAAR Surgical

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from FY2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

FY2023–FY2025 fiscal years

Click a line to see it on the chart.

Revenue

-13.7% a year over 2 years

LineFY2023FY2024FY2025Average a year
Revenue $322M$314M$239M-13.7%
Cost of revenue $70M$74M$57M-9.5%
Gross profit $253M$240M$182M-14.9%
Operating income $28M-$13M-$92M
Net income $21M-$20M-$80M
Earnings per share $0.43-$0.41-$1.62
Earnings per share, basic $0.44-$0.41-$1.62
Margins
Gross margin 78.4%76.3%76.2%
Operating margin 8.7%-4.0%-38.3%
Net margin 6.6%-6.4%-33.6%

Financial statements

STAA's revenue, profits and cash flows from FY2009 to FY2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • FY2018: Implantable Collamer Lenses $101M, Intraocular Lenses $16M, Other Surgical Products $6.7M
  • FY2020: Implantable Collamer Lenses $129M, Intraocular Lenses $16M, Other Surgical Products $5.2M
  • FY2021: Implantable Collamer Lenses $141M, Intraocular Lenses $14M, Other Surgical Products $8.5M
ProductFY2018FY2020FY2021Share FY2021
Implantable Collamer Lenses$101M$129M$141M87%
Intraocular Lenses$16M$16M$14M8.3%
Other Surgical Products$6.7M$5.2M$8.5M5.2%

By segment

STAA's revenue by product line from FY2013 to FY2017, 5 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the XBRL of 11 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$38M Leases2.2% Effective tax rate

Leases

Jan 2, 2026

Operating leases

$38M

Finance leases

–

The liability is the present value of the rent still to pay, at January 2, 2026. It is not counted in the ladder's debt. The filing

Goodwill by segment

Jan 2, 2026

Total goodwill

$1.8M

The company does not state its goodwill by segment, at January 2, 2026. The filing

From the statutory to the effective tax rate, FY2026

Jan 2, 2026

Statutory rate

21.0%

Effective rate

2.2%

-18.8 pts

The company paid 2.2% in tax on its profit, 18.8 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Change in valuation allowance

-8.9 pts

Difference the filing does not itemize

-9.9 pts

Effective rate

2.2%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Earnings quality

How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.

Receivables and inventory against sales

In the quarter to Oct 2, 2026, sales were -12.0% on the same quarter a year earlier, and receivables +44.0%.

  • Days of sales in receivables rose more than at nine in ten S&P 500 companies.
a year earlier 57 days
93 days

Balances at Oct 2, 2026 and Sep 26, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.

Allowance for doubtful accounts

The allowance for receivables that may not be collected was 0.8% of gross receivables at Oct 2, 2026, against 0.1% a year earlier.

a year earlier $83.0K
$720.0K

The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.

The tax part is not shown: a figure it needs is missing from the company's structured filings.

A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.

The full analysis

What do STAAR Surgical's filings show?

These are STAAR Surgical's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about STAA's financials

Didn't find what you were looking for?

Ask us
How much revenue did STAA have in FY2025?

STAAR Surgical had revenue of $239M and net income of -$80M in fiscal FY2025, a net margin of -33.6%.

How much debt does STAA have?

On January 2, 2026 STAAR Surgical had total assets of $452M, debt of – and shareholders' equity of $344M.

How much free cash flow does STAA have?

In fiscal FY2025 STAAR Surgical had cash from operations of -$34M and spent $5.8M on capital expenditure, leaving -$40M of free cash flow.

Where are the figures from?

From STAAR Surgical Company's annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.